SCROLL NEWS / DISCOVERY
Search headlines
Find the stories shaping the conversation.
Results for " therapeutic " 148 found 🔀 AI-powered Shuffle
Political Division Is Damaging Therapeutic Alliances
Opposing views between patients and therapists related to the Palestinian-Israeli conflict have led to ruptured treatment. It is the patients who are harmed.
Garden Grows into Therapeutic Space at Kettering Health Behavioral Medical Center
To boost the behavioral health experience of patients, a therapeutic garden was created at Kettering Health Behavioral Medical Center.
PHA and NAMI host songwriting workshop for Philadelphia youth during Mental Health Awareness Month
The therapeutic songwriting workshop was designed to give young people a creative outlet to discuss their mental health.
TransCelerate Research Examines the Role of Digital Health Technologies in Patient Safety, Published in DIA's Therapeutic Innovation & Regulatory Science
/PRNewswire/ -- TransCelerate BioPharma (TransCelerate), a nonprofit organization dedicated to improving the health of people around the world by accelerating...
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Quantum Cyber (NASDAQ:QUCY) shares increased by 55.0% to $0.5 during Wednesday's pre-market session. The market value of their outstanding shares is at $4.0 million. SELLAS Life Sciences Gr (NASDAQ:SLS) shares increased by 21.26% to $6.33. The market value of their outstanding shares is at $963.2 million. The company's, Q1 earnings came out yesterday. Whitehawk Therapeutics (NASDAQ:WHWK) stock rose 20.17% to $4.71. The market value of their outstanding shares is at $193.8 million. As per
Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results
Company to host conference call and webcast today at 8:00 a.m. EDT Elfabrio commercial execution continues following European Commission approval of the 2...
Relmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Positive 12-Month Phase 2 data for NDV-01 demonstrated a 95% complete response (CR) rate at any time and a durable 76% CR rate at 12 months in high-risk non-muscle invasive bladder cancer (NMIBC), and a 94% CR rate at any time and a durable 80% CR rate at 12 months in the BCG-unresponsive subpopulation, reinforcing best-in-class potential in NMIBCOn track to initiate Phase 3 RESCUE registrational program in second line (2L) BCG-unresponsive and adjuvant intermediate-risk NMIBC in mid-2026Filed p
Pyxis Oncology Appoints Nelson Azoulay as Chief Business Officer
BOSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced the appointment of Nelson Azoulay as Chief Business Officer. Mr. Azoulay joins Pyxis Oncology with more than 15 years of experience in corporate strategy, business development, and value-creating transactions across the biopharma industry, including deep antibody-drug conjugate (ADC) experience. In his role,
Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update
/PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and...
Stanford researchers develop AI scientists for therapeutic discovery
The multi-agent system generated SARS-CoV-2-binding proteins in days.
Iterative Health banks $77m to level up AI-driven clinical research tech
Google Ventures-backed Iterative will now expand its platform into burgeoning therapeutic areas like cardiology and obesity.
Viewpoint: A career in science is possible, and worth it
Starting a career in science is exciting, but also demanding, with researchers often faced with intense competition, long working hours and high levels of stress. A pioneer in the field of mass spectrometry, Carol Robinson has been there. She speaks with Science|Business on the importance of creating a supportive environment, particularly for women.Robinson did not wake up one day thinking that she would become a scientist. It was only late in school that she developed an interest in chemistry. “The more you work at something, the more you think, actually, this is fascinating. So, I went much further and deeper than I ever needed to pass the exam. And then I loved it,” she says. “I thought, I’m going to give it my all. I’m going to enjoy it while I’m here. But I didn’t think this would be my career for 50 odd years.”She left school at 16 to become a lab technician with the drug company Pfizer, which is where she first worked with mass spectrometry. Fascinated, she was encouraged to take a part-time degree and then a PhD. She went on to do pioneering work in native mass spectrometry, a technique that is used to study protein structures in their natural state, paving the way for breakthroughs in drug discovery. She also broke new ground by becoming the first female professor of chemistry at the University of Cambridge, and then the first female professor of chemistry at the University of Oxford, her current home.She now wants to show young researchers that a career in science is worth it. “Sometimes, I believe the culture isn’t very encouraging, and that’s something I have worked on,” Robinson says.In 2021, she launched the Kavli Institute for Nanoscience Discovery at Oxford, whose acronym gives a sense of what she hopes it will achieve. “Maybe it is corny,” she says. “It’s just a reminder that I would like it if we could all be kind to each other and supportive, especially for early-career researchers of either gender, because there’s quite a big attrition rate in science, and maybe it just doesn’t feel like a very friendly place to work.”And yet, a career in science comes with a lot of flexibility. “There are few careers where you have that amount of freedom, to go to conferences, to the library. Just because you didn’t see me didn’t mean I wasn’t working,” she says. “And I’m excited to come in every day. So, I don’t want people to think it’s a terrible place.”Gender equality is also important when it comes to the quality of science as a career. “The more women we have, the better it becomes,” Robinson adds.Imposter syndromeAccording to EU data, women outnumber men in university education but account for just about a third of graduates in science, technology, engineering and mathematics (Stem). And while the number of women working as scientists and engineers in the 27-member bloc is on the rise, their representation remains below that of men, at 41%. This discrepancy is even more pronounced in top-tier functions across these fields, where women fill just 20% of positions.Having supervised many young scientists, Robinson sees that women continue to have a greater propensity than men to doubt their abilities, a feeling she once shared. “When I was doing my PhD at the University at Cambridge, I really felt like an imposter,” she says. “I don’t think I ever felt I deserved to be there or owned it and was proud. I just thought I was lucky.” Later on, she adds, “I was always that person who said, I can’t apply yet because my CV is not strong enough.”She has now made it her job to encourage women to break with this imposter syndrome. For example, rather than calling for volunteers to give a lecture in the groups that she mentors or teaches, which nearly always results in men stepping forward, she goes straight to the women, “because I know they won’t push themselves forward.”But the gender gap in science is not just down to imposter syndrome. The “obvious” reason, Robinson says, and the reason that is on everybody’s mind when discussing workplace gender equality, is the balance between work and raising a family. Her own path was to choose between the two, taking an eight-year break after completing a postdoctoral training fellowship to bring up three children. And she continues to advise women not to work part-time while they raise a family. “You’ll just get half the pay and continue to work full-time because you are not able to fit everything in,” she says. “You should be able to have a family and come back to have the career that you want.”The solution is for men to also take career breaks. “That kind of evens it up, so that it’s not such a big thing for women,” Robinson says. “I always encourage men in my groups to do that. I think it’s important to take your share of the duties.”Support produces resultsAccording to the Women in Stem Network, a UK advocacy group, countries with strong childcare systems and equal pay policies retain more women in technical careers. In Europe, these are primarily found in the Nordic region and parts of central Europe.At the EU level, the European Commission asks all Horizon Europe applicant organisations to have a gender action plan in place. Since this criterion was introduced in 2021, the share of women leading consortia has increased to 31%, against 23% in Horizon 2020. Their overall participation, however, has risen just 1%, to 38%. After trying to weaken the requirement for gender action plans in 2025, the Commission now intends to adopt a plan for supporting women in research and innovation.Related articlesCommission scraps plan to water down gender requirements in HorizonHow gender balance can swing who wins Horizon Europe fundingRobinson herself has benefited from three Advanced Grants from the European Research Council. “I was extremely honoured and privileged to get those, because they really allowed me to fuel my passion,” she says. “Without that, it would have been a much harder slog.”Beyond applying gender rules, she says that more work is needed on translational enterprise, where women are, once again, largely underrepresented. The European Patent Office found that only 13.8% of applications were filed by women in 2022. “We have so many more women doing amazing science; why do they feel it’s not a thing to have a company?” she asks.She founded her own spin-out company, OMass Technologies, in 2016, and remains chair of its scientific advisory board now that it trades as OMass Therapeutics. As for research, Robinson is now studying how changes in the brain may be linked to depression, using port-mortem tissue. “We’re hoping to publish soon,” she says. “We had to consult with a lot of people who knew a lot more about the brain than we did. So, we’ve learnt a lot, and that’s always a lot of fun to learn a new thing. That’s what keeps you going.”
Cedars-Sinai Event Explores Ethics of Longevity Science
Cedars-Sinai experts and prominent scholars of religion, Jewish law and ethics are coming together on May 3 for a free public discussion focusing on the ethical, moral and theological questions that can result from medical breakthroughs.
Mechanohealth: Where life science meets physical forces for health innovation
Integrating mechanobiological principles into disease pathogenesis, therapeutic development, and tissue engineering is reshaping our understanding of biological systems and accelerating the advancement of mechanotherapy and mechanohealth. This field reveals how mechanical cues regulate cellular behavior, such as force transmission along integrin-nucleus pathways and collective cell migration, and tissue functions. In doing so, mechanobiology connects fundamental research with clinical applications, from limiting cancer metastasis and fibrosis to promoting bone regeneration and maintaining vascular homeostasis. Building on discussion from the Inaugural International Conference on Mechanobiology (ICM) 2025, integrating mechanobiological research with clinical strategies offers new opportunities to address unmet needs, including personalized anti-fibrotic interventions or precision bone regenerative therapies. At the same time, it supports the broader concept of mechanohealth -- a paradigm focused on preserving the physiological mechanical balance within tissues.
Trump is savaging allies who criticize the Iran war. But he’s treating Joe Rogan very differently
The way Joe Rogan tells it, about all President Donald Trump needed before he fast-tracked research into therapeutic uses for certain psychedelic treatments like Ibogaine was a text from a podcaster.
Trump Signs Order To Accelerate Legal Access To Psychedelics For Patients With Mental Health Conditions
President Donald Trump has signed an executive order aimed at expanding and expediting research on the potential therapeutic benefits of psychedelics, a move aimed at making substances such as psilocybin, ibogaine, LSD and MDMA more readily available to patients in clinical settings. The move will “dramatically accelerate access to new medical research and treatments based […]
Apollo Health Ventures launches new start-up with $20 million in federal funds
An award from ARPA-H is powering Nula Therapeutics
How does mitochondrial DNA affect your health? - Salk Institute for Biological Studies
Highlights Salk scientists have created a platform to study mitochondrial DNA mutations that lead or contribute to human disease They generated a library of 155 mitochondrial DNA mutant cells, nearly the human level of mitochondrial DNA mutant diversity The platform and library will accelerate innovation in the mitochondrial disease therapeutic space LA JOLLA—Some of your most important life partners are the mitochondria that power all your cells. You and these little cellular powerhouses are in a 1.5-billion-year-old evolutionary relationship—but mitochondria brought some baggage. Mitochondria brought their own DNA with them when they joined with the bigger, more complex cells so long ago, and today that mitochondrial DNA influences human health.
Iterative Health, US Heart & Vascular Partner to Advance Community-Based Cardiovascular Research
April 2, 2026 — Iterative Health and US Heart & Vascular (USHV) have announced a strategic partnership to advance research through community-based innovation in cardiovascular care. "Clinical research is one of the most powerful ways we expand access, improve patient outcomes, and shape the future of cardiovascular care," said Robbie Allen, chief executive officer of US Heart & Vascular. "By partnering with Iterative Health, we are strengthening our ability to bring innovative therapies directly into the communities we serve. This collaboration ensures our physicians and patients have access to leading-edge trials while allowing US Heart & Vascular to remain focused on delivering exceptional, physician-led care." Under the agreement, USHV research sites will join Iterative Health’s global site network, which now spans over 100 sites across three continents. The companies share a commitment to advancing clinical research as a driver of care innovation, and this collaboration represents a major milestone for both organizations, strengthening USHV's leadership in community-based cardiovascular research and expanding Iterative Health's multispecialty focus beyond GI, hepatology, and obesity into cardiology. USHV clinical research sites will gain access to Iterative Health's centralized operational backbone, providing end-to-end support across clinical research operations, services, business development, technology innovation, and corporate functions. The strategic partnership reduces operational complexity and unlocks growth potential for USHV research sites while enabling all USHV physicians to expand access to cutting-edge therapies to the thousands of patients they serve annually. "Innovation in cardiovascular medicine shouldn't be limited to a few academic centers," said Thomas Waggoner, DO, MD, RPVI, FACC, FSCAI, FSVM, RPVI, Structural Cardiologist and Medical Director for Clinical Research at Pima Heart & Vascular, and USHV Physician Champion for Clinical Research. "By expanding community-based research across USHV, we're ensuring more patients have access to clinical trials and breakthrough therapies close to home, where trusted relationships with their physicians already exist." This alliance reinforces Iterative Health's standing as the definitive research partner across specialized therapeutic areas, now spanning GI, hepatology, obesity, and cardiovascular care. Trusted by many of the nation's leading provider organizations and biopharma sponsors, Iterative Health's global site network delivers industry-leading trial performance, accelerating life-changing therapies to market at scale. "Entering cardiology through our strategic partnership with US Heart & Vascular is a defining moment for Iterative Health and reflects the strength of our site-serving model," said Jonathan Ng, founder and CEO of Iterative Health. "Together, we are ensuring that thousands of patients have access to the newest available therapies, and that sponsors have a credible, high-performing partner to accelerate cardiovascular trial success." For more information, visit www.iterative.health and https://usheartandvascular.com/.
RPI Announces DOE Under Secretary for Science and CEO of Melinta Therapeutics as Commencement Honorands
Rensselaer Polytechnic Institute (RPI) today announced that Darío Gil, Ph.D., Under Secretary for Science at the U.S.
Stealth BioTherapeutics Announces MRC Business Engagement Fund Grant to Advance Mitochondrial Disease Research
/PRNewswire/ -- Stealth BioTherapeutics (the "Company"), a commercial-stage biotechnology company focused on the discovery, development, and commercialization...
Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results
Company to host conference call and webcast today at 8:00 a.m. EDT The European Commission (EC) approved the 2mg/kg every-4-weeks (E4W) dosing regimen for...
Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results
Company to host conference call and webcast today at 8:00 a.m. EDT The European Commission (EC) approved the 2mg/kg every-4-weeks (E4W) dosing regimen for...
Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results
CAMBRIDGE, England & BOSTON, March 17, 2026--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided recent corporate updates.
The scientist who warned that profit, not science, decides which drugs reach patients
In a Genomic Press Interview published in Brain Medicine, Dr. Gabriella Gobbi, Professor of Psychiatry at McGill University, Canada Research Chair (Tier 1) in Therapeutics for Mental Health, and President-Elect of the Collegium Internationale of Neuropsychopharmacology (CINP), delivers a pointed warning: the greatest threat to drug discovery is not scientific failure but a financing system that abandons effective, affordable treatments whenever they cannot promise sufficient returns to investors. Across a career that began in central Italy and moved through Sardinia and Montreal, Dr. Gobbi has generated landmark research linking adolescent cannabis exposure to depression, identified novel melatonin receptor mechanisms in sleep and pain, and launched psychedelic neuroscience before it became fashionable. The interview reveals a scientist whose best questions have always begun at the bedside, and whose most urgent fears concern the structures that stand between discovery and patients.
Integrated Crisis Stabilization Services supports individuals experiencing substance use and mental health crises at United Counseling Service’s Battelle House in Bennington, VT
As part of a State of Vermont request, United Counseling Service (UCS) created an Integrated Crisis Stabilization Program (ICSS) this year to expand its services for individuals experiencing mental health and substance use crises in Bennington County. ICSS provides therapeutic groups, skill-building, and a safe place to recover.
Just 24 minutes of specially designed music could significantly reduce anxiety
A clinical trial found that listening to specially designed music with auditory beat stimulation can significantly reduce anxiety. Among several listening lengths tested, a 24-minute session delivered the biggest benefits, easing both mental and physical symptoms of anxiety. The results suggest there may be an ideal “dose” of therapeutic music that works quickly without requiring long listening sessions.
Scientists find a new therapeutic target present on up to half of all tumors
For five decades, scientists have known about a notorious cancer-causing enzyme called SRC. But they always assumed it only appeared on the inside of cells, where it sent signals that fueled tumor growth ...
Century Therapeutics Reports Full Year 2025 Financial Results and Business Updates
CNTY-813, lead beta islet cell therapy program as a potential functional cure for type 1 diabetes, in Investigational New Drug (IND)-enabling studies; IND submission expected in 4Q 2026 to support anticipated initial clinical data in 2H 2027CNTY-308, a CD19-targeted CAR-iT cell therapy engineered with Allo-Evasion™ 5.0, on track to enter the clinic in 2026Strengthened balance sheet and cash runway extended into 1Q 2029 from oversubscribed $135 million private placement in January 2026 PHILADELPH
Protalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business Update on March 18, 2026
/PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production and...
Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights
Initial clinical response data for AlloNK® in refractory rheumatoid arthritis (RA) expected in first half of 2026 U.S. Food and Drug Administration (FDA) interaction to discuss potential pivotal trial design for AlloNK expected in first half of 2026 Strengthened board and executive leadership with deep immunology, commercial and financial expertise Robust balance sheet with cash, cash equivalents and investments of $108.0 million as of December 31, 2025, expected to fund operations into Q2 2027
EQT Foundation opens applications for science grants to overcome the blood-brain barrier and transform CNS drug delivery
EQT Foundation is launching a new open call for proposals under its Science Grants program, focused on breakthrough innovations to cross or modulate the blood-brain barrier (BBB) for therapeutic delivery to the central nervous system. The program will award catalytic, non-dilutive grants of €25,000 to €100,000 to researchers developing high-risk, high-impact deeptech solutions with the potential to unlock a new era of Central Nervous System (CNS) medicine. Designed to accelerate bold scientific
Cartesian Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update
Enrollment continues to progress in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis Phase 2 TRITON trial of Descartes-08 in dermatomyositis and antisynthetase syndrome, expected to initiate in 1H26 Phase 1/2 HELIOS pediatric trial of Descartes-08 in juvenile dermatomyositis actively enrolling Approximately $126.9 million cash, cash equivalents and restricted cash as of December 31, 2025, expected to support planned operations into mid-2027, including completion of ongoing Phase 3 AUROR
Got $10,000? Axsome Therapeutics Could Be a Mental‑Health Moonshot by 2036
The biotech is slowly rising in prominence.
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
ZUG, Switzerland and BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the fourth quarter and full year ended December 31, 2025. “As we close out the fourth quarter, CRISPR Therapeutics continues to make steady progress across a broad and increasingly mature pipeline,” said Samarth Kulkarni, Ph.D., Chairman and Chief Executive Officer of CRISPR Therapeutics. “We made meaningful advances across multiple clinical and preclinical progr
Big Health raises funding as investors see glimmer of hope for digital therapeutics
Big Health raises $24 million as investors bet that digital therapeutics' time has finally arrived.
Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Financial and Business Officer
BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune and inflammatory diseases, today announced that Lucinda Warren, who has served as Cue Biopharma’s chief business officer (CBO) since September 2024, has been appointed chief financial and business officer (CFBO) effective February 9, 2026
Cancer vaccine shows promise against HPV-related throat tumors in early study
If proven effective in humans, the vaccine could complement standard therapies for HPV-driven cancer, as well as inform the design of therapeutic vaccines for other diseases.
Designing the future of metabolic health through tissue-selective drug delivery
Founded by MIT alumni, the biotech firm Gensaic develops protein carriers that can deliver therapeutic molecules to specific tissues and cells.
Entrepreneurs Organization isn't therapy, but it can be therapeutic, the local chapter president says
The Baton Rouge-based ad executive is president of the Louisiana chapter of Entrepreneurs Organization, which connects business founders with their peers and helps them learn how to grow their companies.
Health Care Roundup: Market Talk
Find insight on GSK’s acquisition of RAPT Therapeutics, Novartis and more in the latest Market Talks covering Health Care.
Women's Health Investment Outlook
Despite women and girls making up nearly half the world’s population, women’s health has captured just 6% of private healthcare investment. More than 25 organizations from the investment community, industry, philanthropies and beyond provided insights for this report, which addresses critical gaps in understanding investment flows in women’s health, market opportunity and unmet need. To quantify private investment flows in women’s healthcare over the past five years, the report introduces the Women’s Health Investment Index. Major areas of unmet need and opportunity across high-burden, high-prevalence conditions that affect women uniquely, differently and disproportionately – such as cardiovascular disease, osteoporosis, menopause and Alzheimer’s disease – have been overlooked. A recent analysis by the Boston Consulting Group (BCG) estimates that effectively addressing these four therapeutic areas for women in the US could unlock a $100 billion-plus market opportunity by 2030.
Women's Health Investment Outlook
Despite women and girls making up nearly half the world’s population, women’s health has captured just 6% of private healthcare investment. More than 25 organizations from the investment community, industry, philanthropies and beyond provided insights for this report, which addresses critical gaps in understanding investment flows in women’s health, market opportunity and unmet need. To quantify private investment flows in women’s healthcare over the past five years, the report introduces the Women’s Health Investment Index. Major areas of unmet need and opportunity across high-burden, high-prevalence conditions that affect women uniquely, differently and disproportionately – such as cardiovascular disease, osteoporosis, menopause and Alzheimer’s disease – have been overlooked. A recent analysis by the Boston Consulting Group (BCG) estimates that effectively addressing these four therapeutic areas for women in the US could unlock a $100 billion-plus market opportunity by 2030.
ESTEVE to acquire TerSera Therapeutics' Infusion Specialty Therapies Business Unit, Expanding U.S. presence
/PRNewswire/ -- ESTEVE and TerSera Therapeutics LLC announced today that they have entered into an agreement in which ESTEVE will acquire TerSera's Infusion...
ESTEVE to Acquire TerSera Therapeutics’ Infusion Specialty Therapies Business Unit, Expanding U.S. Presence
BARCELONA & DEERFIELD, Ill., January 13, 2026--ESTEVE and TerSera Therapeutics LLC announced today that they have entered into an agreement in which ESTEVE will acquire TerSera’s Infusion Specialty Therapies Business Unit (IST). This strategic acquisition enables ESTEVE to expand its U.S. presence, with two highly specialized on-market assets and a dedicated team of sales, marketing and medical professionals.
The New WHO Pandemic Treaty and Global Health Governance: Incorporating Common but Differentiated Responsibilities into PABS - Georgetown Journal of International Affairs
On May 20, 2025, the World Health Assembly unanimously adopted the World Health Organization (WHO) Pandemic Agreement, an international treaty designed to strengthen pandemic prevention, preparedness, and response. The product of three years of arduous negotiations, the treaty marks a new era of global cooperation in public health. However, core aspects of the agreement remain unresolved—notably the Pathogen Access and Benefit-Sharing (PABS) System, which is intended to ensure equitable access to pandemic-related materials and benefits. To support the successful implementation of the WHO Pandemic Agreement, the principle of “common but differentiated responsibilities” should be formally incorporated into the negotiating agenda of the PABS annex. Introduction For the first time, an international treaty has enshrined the principle of “One Health,” the compelling idea that the health of animals, humans, and the environment all contribute to pandemic risks. SARS (2003), H1N1 (2009–10), Ebola (2014–16), and COVID-19 all emerged through zoonotic spillover from animal hosts—respectively, civets, hogs, and bats. Together, they underscore the need for a coordinated, cross-sectoral approach. The Pandemic Agreement responds to this call, requiring state parties to acknowledge the ecological interplay and commit to a comprehensive “One Health” strategy. Specifically, Article 5 charges governments to address “the drivers of pandemics and the emergence and re-emergence of infectious disease at the human-animal-environment interface,” including wild animal markets, deforestation, and antibiotic overuse. Yet the effectiveness of this “One Health” vision depends equally on the free flow of scientific information and data among countries and institutions. Just as environmental and animal health factors have been neglected in past global frameworks, so too has data sharing been marginalized, despite its centrality to timely detection and response. The Pandemic Agreement takes an important step by requiring governments to enhance data collection and cooperate with the World Health Organization (WHO). However, these provisions will remain aspirational without a robust Pathogen Access and Benefit-Sharing (PABS) annex. The PABS system will determine whether countries and researchers can rapidly exchange pathogen samples and genetic data while ensuring equitable access to resulting research and development, including diagnostics, therapeutics, and vaccines. Without such mechanisms, the treaty’s promise to operationalize “One Health” and strengthen global preparedness will risk becoming largely symbolic, echoing earlier failures to translate shared principles into coordinated action. Equity Concerns When the 2025 Health Assembly adopted the Pandemic Agreement, it left the difficult question of access to pathogens and the sharing of resulting benefits to be addressed in a separate agreement. Negotiations on this separate agreement, PABS, are now underway in Geneva. Yet governments remain divided over fundamental questions of equity between the countries that primarily contribute to the system and those that primarily draw from it—and consequently benefit. For example, wildlife in countries bordering the equator is likely to produce PABS materials, but companies in Europe are likely to use them to develop lucrative products. The most likely contributor countries are likely to be those biodiverse countries around the equator, such as Brazil, the Democratic Republic of the Congo, and Indonesia, where the number of human-mammalian viral host interactions is large. Conversely, countries most likely to benefit from this material are those with the technology, investors, and infrastructure to capitalize on genomic data, such as the United States, EU member states, and Japan. This imbalance reflects a broader pattern seen in prior international frameworks. Now, as in the past, the wealthiest countries in the world (a useful heuristic is membership of the Organisation for Economic Co-operation and Development (OECD)) disproportionately benefit from systems in which pathogens and genomic sequencing data are contributed to a common source. Under the International Agreement on Plant Genetic Resources for Food and Agriculture (the “Plant Treaty” or “Seed Treaty”) and the Pandemic Influenza Preparedness (PIP) Framework, companies from Europe and North America disproportionately withdraw biological samples and data for development into lucrative medical products. Their governments and companies have both statutory and contractual claims to the products that those companies correspondingly produce. PABS appears poised to follow the same pattern. The text calls for strong language on access to pathogens and associated data, but the corresponding benefits that should flow to poorer countries are couched in equivocal or non-binding language. Common but Differentiated Responsibilities To address these inequities, the principle of “common but differentiated responsibilities” should be formally incorporated into the negotiating agenda of the PABS annex. Common but differentiated responsibilities are often a feature of climate change negotiations. The basic principle is that, even though all countries should reduce carbon emissions, governments that became rich and powerful through massive carbon emissions (e.g., France, the United Kingdom, the United States) should have a greater obligation to address the resulting crises. Applied to PABS, it would require that governments hosting and supporting companies developing lucrative products carry greater obligations toward the cost of running the PABS system; share benefits or final medical products; and transfer technology to help countries worldwide develop their own capacities to innovate and manufacture vaccines during an emergency. For example, an annex could mandate that any company based in an OECD country that withdraws PABS material would be obligated to donate the resulting diagnostics, therapeutics, or vaccines to the WHO during a public health emergency or pandemic. Questions remain about how robust those donations would be, but the principle is that they should deliver highly significant lifesaving benefits to be equitably shared. Theoretically, this approach mirrors the PIP Framework, in which companies withdrawing influenza samples are required to pay half of the operating costs. In practice, however, the framework has fallen short. The PIP Framework Secretariat has struggled to secure payments from companies, with companies often disagreeing over how much is owed. Additionally, without another pandemic influenza to test the strength of the agreement during a public health emergency, corporate compliance with sharing mechanisms remains unknown. Even if these limitations did not characterize the PIP Framework, partially paying for operating expenses does not address the inequity in access to genetic data and pathogen samples that left less developed countries last in line for COVID-19 vaccines (and, before them, H1N1). Common but differentiated responsibilities would go further, addressing governments’ legitimate grievances regarding information sharing. It would make withdrawals of PABS material and resulting products more transparent, building trust across the board. Enforcement and Enduring Success A key implication of this approach is that the governing mechanism of the PABS must have real enforcement authority. The WHO Pandemic Agreement delegates its core governance responsibilities to a Conference of the Parties (COP)—a governing body composed of one representative from each participating government, similar to those established under the UN Framework Convention on Climate Change and the WHO Framework Convention on Tobacco Control. The proposed WHO Pandemic Agreement COP is charged with oversight functions but ultimately possesses no real authority to compel a government to take any action it does not wish to take. The text does not give the COP the ability to, for example, sanction a party that does not comply with either textual obligations or PABS provisions. In other words, there are no effective mechanisms in place to ensure compliance. Perhaps just as significant, establishing a meaningful enforcement mechanism within the PABS system would strengthen the WHO’s credibility and its ability to ensure compliance across global health governance. By setting a precedent for accountability, such a mechanism could enhance the organization’s authority not only within the Pandemic Agreement but also in enforcing the revised International Health Regulations and other frameworks for public health emergencies. Conclusion The PABS annex can—and should—be different. It should establish clear responsibilities for funding as well as for sharing the diagnostics, therapeutics, and vaccines that result from contributions to the system. The system, in turn, must include a dedicated body empowered to hold governments and the corporations they sponsor accountable for their responsibilities before, during, and after pandemics. Doing so would restore trust in the broader agreement, which was eroded as commitments were repeatedly diluted while parties scrambled to meet their own self-imposed deadlines during the Pandemic Agreement negotiations. A robust PABS Annex would cement a grand social bargain. Wealthier countries and their corporations would gain unimpeded access to scientific information essential for developing and manufacturing lifesaving medical products. As such, they would stand to gain considerable economic benefit. Yet that privilege must be matched with responsibility. The grand bargain must include not only the right to innovate, but also the duty to ensure that innovation serves all. As medical products are developed and produced through collective contributions, every person must have equal access. All human beings deserve an equitable chance to survive—to save their own life, the lives of their families, and the well-being of their communities. … Sam Halabi, JD, MPhil, is the Bette Jacobs Endowed Professor at Georgetown University’s School of Health and the Director of the Center for Transformational Health Law at Georgetown Law. He serves as the co-lead for the WHO’s Working Group on Regulatory Consideration on AI and Health’s training workstream. He earned his JD from Harvard, his MPhil from Oxford, and undergraduate degrees from Kansas State University. Lawrence Gostin, LLD (Hon.), JD, BA, is University Distinguished Professor and Founding Director and Timothy and Linda O’Neill Professor of the O’Neill Institute for National and Global Health Law. He is the author of Global Health Security: A Blueprint for the Future (Harvard University Press, 2021); Global Health Law (Harvard University Press, 2014); Public Health Law: Power, Duty, Restraint (University of California Press, 3rd ed., 2016); Public Health Law and Ethics: A Reader (University of California Press, 3rd ed., 2018); Law and the Health System (Foundation Press, 2014); Principles of Mental Health Law & Practice (Oxford University Press, 2010). He also directs the WHO Collaborating Center at Georgetown University. Image Credit: United States Mission Geneva, CC BY 2.0, via Wikimedia Commons
UT Southwestern biochemist to receive O’Donnell Award from TAMEST
Yunsun Nam, Ph.D., Professor of Biochemistry and Biophysics at UT Southwestern Medical Center, will receive the 2026 Edith and Peter O’Donnell Award in Biological Sciences from the Texas Academy of Medicine, Engineering, Science & Technology (TAMEST) for her research into how RNAs and proteins interact at the molecular level. Her work has shed light on gene regulation, cancer biology, and RNA-based therapeutics.
PTC Therapeutics Announces Health Canada Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU)
PTC Therapeutics Canada ULC announced that Health Canada has approved Sephience™ (sepiapterin) for the treatment of children and adults living with phenylketonuria (PKU). The approval includes broad labeling for the treatment of hyperphenylalaninemia (HPA) in adult and pediatric patients 1 month old and older with sepiapterin-responsive PKU.